Nanotechnologies in protein delivery

Journal of Nanoscience and Nanotechnology

Volumn 6, Issue 9-10, 2006, Pages 2736-2753

  Salmaso, Stefano ^a   Bersani, Sara ^a   Semenzato, Alessandra ^a   Caliceti, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bioconjugates; Nanoparticles; Polymer Therapeutics; Protein Delivery; Supramolecular Systems

Indexed keywords

BIOCONJUGATES; POLYMER THERAPEUTICS; PROTEIN DELIVERY; SUPRAMOLECULAR SYSTEMS;

BIOTECHNOLOGY; DRUG PRODUCTS; PROTEINS; SUPRAMOLECULAR CHEMISTRY;

NANOTECHNOLOGY;

BIOMATERIAL; DRUG CARRIER; NANOMATERIAL; POLYMER; PROTEIN;

CHEMISTRY; CRYSTALLIZATION; METHODOLOGY; NANOTECHNOLOGY; PARTICLE SIZE; REVIEW;

COATED MATERIALS, BIOCOMPATIBLE; CRYSTALLIZATION; DRUG CARRIERS; NANOSTRUCTURES; NANOTECHNOLOGY; PARTICLE SIZE; POLYMERS; PROTEINS;

EID: 33750047524     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: 10.1166/jnn.2006.456     Document Type: Conference Paper

References (166)

1. J. A. Borgia and G. B. Fields, Trends Biotechnol. 18, 243 (2000).
2. D. T. Molowa and R. Mazanet, Biotechnol. Ann. Rev. 9, 285 (2003).
3. H. Schellekens, Trends Biotechnol. 22, 406 (2004).
4. G. Walsh, Trends Biotechnol. 23, 553 (2005).
5. J. L. Cleland, A. Daugherty, and R. Mrsny, Curr. Opinion. Biotechnol. 12, 212 (2001).
6. G. Drive, R. M. Hernández, R. A. Gascón, A. Domínguez-Gil, and L. J. Pedraz, Curr. Opinion Biotechnol. 14, 659 (2003).
7. E. J. McNall (Ed.), Protein formulation and Delivery, Marcel Dekker, New York (2000).
8. Drug Delivery: New Technologies in the Global Market, Vision-Gain (2003), (www.the-infoshop.com).
9. R. H. Muller and C. M. Keck, J. Biotechnol. 113, 151 (2004).
10. S. K. Sahoo and V. Labhasetwar, Drug Discov. Today. 8, 1112 (2003).
11. P. Couvreur, G. Barratt, E. Fattal, P. Legrand, and C. Vauthier, Crit. Rev. Ther. Drug Carrier Syst. 19, 99 (2002).
12. B. N. Violand and N. R. Siegel, Peptide and Protein Drug Analysis, in Protein and Peptide Chemical and Physical Stability, edited by R. E. Reid, Marcel Dekker, New York (2000), pp. 257-284.
13. M. C. Manning, K. Patel, and R. T. Borchardt, Pharm. Res. 6, 903 (1989).
14. J. L. Cleland, M. F. Powell, and S. J. Shire, Crit. Rev. Ther. Drug. Carrier Syst. 10, 307 (1993).
15. V. H. L. Lee (Ed.), Peptide and Protein Drug Delivery, Marcel Dekker, New York (1991).
16. B. Kompella and V. H. L. Lee, Pharmacokinetics of Peptide and Protein Drugs, in Peptide and Protein Drug Delivery, edited by V. H. L. Lee, Marcel Dekker, New York (1991), p. 391.
17. K. L. Audus and T. J. Raub (Eds.), Biological Barriers in Protein Delivery, Plenum Press, New York (1993).
18. R. Rabkin and D. C. Dahl, Renal Uptake and Disposal of Proteins and Peptides. in Biological Barriers in Protein Delivery, edited by K. L. Audus and T. J. Raub, Plenum Press, New York (1993), p. 299.
19. H. Sato, Y. Sugiyama, A. Tsuji, and I. Horikoshi, Adv. Drug Deliv. Rev. 19, 445 (1996).
20. J. Brange and A. Vølund, Adv. Drug Deliv. Rev. 35, 307 (1999).
21. A. C. Kotto-Kome, S. E. Fox, L. Wenge, Y. Bing-Bing, R. D. Christensen, and D. A. Calhoun, Pharmacol. Res. 50, 55 (2004).
22. M. Hashida, M. Nishikawa, F. Yamashita, and Y. Takakura, Adv. Drug Deliv. Rev. 52, 187 (2001).
23. E. O. Donald and N. A. Peppas, Int. J. Pharm. 307, 93 (2006).
24. H. Schellekens and N. Casadevall, J. Neurol. 251 (Suppl II), 4 (2004).
25. P. Pirazzoli, E. Cacciari, M. Mandini, A. Cicognani, S. Zucchini, T. Sganga, and M. Capelli, Acta Paediatr. 84, 1233 (1995).
26. V. P. Torchilin and A. N. Lukyanov, Drug Discov. Today. 15, 259 (2003).
27. G. M. Barratt, Pharm. Sci. Technol. Today. 3, 163 (2000).
28. P. Couvreur, C. Dubernat, and F. Puisieux, Eur. J. Pharm. Bio-pharm. 41, 2 (1995).
29. D. J. Begley, Pharmacol. Ther. 104, 29 (2004).
30. A. T. Florence, Pharm. Res. 14, 259 (1997).
31. T. Jung, W. Kamm, A. Breitenbach, E. Kaiserling, J. X. Xiao, and T. Kissel, Eur. J. Pharm. Biopharm. 50, 147 (2000).
32. J. Kreuter, Adv. Drug Deliv. Rev. 7, 71 (1991).
33. H. Oya Alpar, S. Somavarapu, K. N. Atuah, and V. W. Bramwell, Adv. Drug Deliv. Rev. 57, 411 (2005).
34. X. Li, Y. Zhang, R. Yan, W. Jia, M. Yuan, X. Deng, and Z. Huang, J. Control. Rel. 68, 41 (2000).
35. M. C. Lai and E. M. Topp, J. Pharm. Sci. 88, 489 (1999).
36. E. Reverchon and R, Adami, J. Supercritical Fluids. 37, 1 (2006).
37. P. J. Ginty, M. J. Whitaker, K. M. Shakesheff, and S. M. Howdle, Materials Today. 8, 42 (2005).
38. S. D. Yeo and E. Kiran, J. Supercritical Fluids. 34, 287 (2005).
39. P. Caliceti, N. Elvassore, and A. Bertucco, J. Pharm. Sci. 90, 1628 (2001).
40. P. Caliceti, S. Salmaso, N. Elvassore, and A. Bertucco, J. Control. Rel. 94, 195 (2004).
41. D. J. A. Crommelin, G. Storm, W. Jiskoot, R. Stenekes, E. Mastrobattista, and W. E. Hennink, J. Control. Rel. 87, 81 (2003).
42. S. Salmaso, P. Caliceti, N. Elvassore, A. Bertucco, and A. Lante, Int. J. Pharm. 287, 163 (2004).
43. M. van de Weert, W. E. Hennink, and W. Jiskoot, Pharm. Res. 17, 1159 (2000).
44. U. Bilati, E. Allémann, and E. Doelker, Eur. J. Pharm. Biopharm. 59, 375 (2005).
45. U. Bilati, E. Allémann, and E. Doelker, Eur. J. Pharm. Sci. 24, 67 (2005).
46. S. P. Schwendeman, M. Cardamone, M. R. Brandon, A. Klibanov, and R. Langer, Stability of Proteins and Their Delivery from Biodegradable Polymer Microspheres. in Microparticulate Systems for the Delivery of Proteins and Vaccines, edited by S. Cohen and H. Bernstein, Marcel Dekker, New York (1996).
47. G. Zhu, S. R. Mallery, and S. P. Schwendeman, Nat. Biotechnol. 18, 52 (2000).
48. J. Szebeni and S. M. Moghimi, Progr. Lipid Res. 42, 463 (2003).
49. C. Passirani and J. P. Benoit, Complement Activation by Injectable Colloidal Drug Carriers, in Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids, edited by R. I. Mahato, CRC Press, Florida, USA (2005), pp. 187-230.
50. A. Gessner, A. Lieske, B. R. Paulke, and R. H. Müller, Eur. J. Pharm. Biopharm. 54, 165 (2002).
51. B. Heurtault, P. Saulnier, B. Pech, J. E. Proust, and J. P. Benoit, Biomaterials. 24, 4283 (2003).
52. S. P. Baldwin and W. M. Saltzman, Adv. Drug Deliv. Rev. 33, 71 (1998).
53. S. Zhang, Biotechnol. Adv. 20, 321 (2002).
54. G. A. Hughes, Biology and Medicine 1, 22 (2005).
55. A. G. Mamalis, L. O. G. Vogtländer, and A. Markopoulos, Precision Eng. 28, 16 (2004).
56. D. Cui, Biotechnol. Prog. 19, 683 (2003).
57. J. Panyam and V. Labhasetwar, Adv. Drug Deliv. Rev. 55, 329 (2003).
58. K. S. Soppimath, T. S. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski, J. Control. Rel. 70, 1 (2001).
59. A. Sanchez, M. Tobío, L. Gonzalez, A. Fabra, and M. J. Alonso, Eur. J. Pharm. Sci. 18, 221 (2003).
60. R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer, Science 263, 1600 (1994).
61. R. Gref, Surface-Engineered Nanoparticles as Drug Carriers, in Synthesis, Functionalization, and Surface Treatment of Nanoparticles, edited by M. I. Baraton, American Scientific Publishers, New York (2002), pp. 233-256.
62. S. Stolnik, B. Daudali, A. Arien, J. Whetstone, C. R. Heald, M. C. Garnett, S. S. Davis, and L. Illum, Biochim. Biophys. Acta. 1514, 261 (2001).
63. L. A. Dailey and T. Kissel, Drug Discovery Today: Technol. 2, 7 (2005).
64. H. Gao, Y. Wang, N. Y., G. Fan, and J. B. Ma, J. Control. Rel. 107, 158 (2005).
65. C. Fang, B. Shi, Y. Y. Pei, M. H. Hong, J. Wu, and H. Z. Chen, Eur. J. Pharm. Sci. 27, 27 (2006).
66. Y. P. Li, Y. Y. Pei, Z. H. Zhou, X. Y. Zhang, Z. H. Ou, J. Ding, J. J. Zhou, X. J. Gao, and J. H. Zhu, Biol. Pharm. Bull. 24, 662 (2001).
67. J. Kreuter, R. Alyautdin, D. Kharkevich, and A. Ivanov, Brain Res. 674, 171 (1995).
68. S. Sakuma, M. Hayashi, and M. Akashi, Adv. Drug Deliv. Rev. 47, 21 (2001).
69. A. Ludwig, Adv. Drug Deliv. Rev. 57, 1595 (2005).
70. J. S. Rodrigues, N. S. Santos-Magalhães, L. C. B. B. Coelho, P. Couvreur, G. Ponchel, and R. Gref, J. Control Rel. 92, 103 (2003).
71. A. Vila, A. Sánchez, M. Tobío, P. Calvo, and M. J. Alonso, J. Control. Rel. 78, 15 (2002).
72. K. A. Janes, P. Calvo, and M. J. Alonso, Adv. Drug Deliv. Rev. 47, 83 (2001).
73. M. M. Issa, M. Köping-Höggård, and P. Artursson, Drug Discovery Today: Technol. 2, 1 (2005).
74. L. Illum, I. Jabbal-Gill, M. Hinchcliffe, A. N. Fisher, and S. S. Davis, Adv. Drug Deliv. Rev. 51, 81 (2001).
75. P. Calvo, C. Remunán-López, J. L. Vila-Jato, and M. J. Alonso, J. Appl. Polym. Sci. 63, 125 (1997).
76. Y. Xu, Y. Du, R. Huang, and L. Gao, Biomaterials. 24, 5015 (2003).
77. Y. Xu and Y. Du, Intern. J. Pharm. 250, 215 (2003).
78. S. Iijima and T. Ichihashi, Nature 363, 603 (1993.
79. A. Bianco, K. Kostarelos, C. D. Partidos, and M. Prato, Chem. Commun. 9, 571 (2005).
80. N. W. S. Kam, T. C. Jessop, P. A. Wender, and H. Dai, Am. Chem. Soc. 126, 6850 (2004).
81. D. Pantarotto, C. D. Partidos, J. Hoebeke, F. Brown, E. Kramer, J. P. Briand, S. Muller, M. Prato, and A. Bianco, Chem. Biol. 10, 961 (2003).
82. T. Murakami, K. Ajima, J. Miyawaki, M. Yudasaka, S. Iijima, and K. Shiba, Mol. Pharm. 1, 399 (2004).
83. Z. P. Xu, Q. H. Zeng, G. Q. Lu, and A. B. Yu, Chem. Eng. Sci. 61, 1027 (2006).
84. N. Venkatesan, J. Yoshimitsu, Y. Ito, N. Shibata, and K. Takada, Biomaterials. 26, 7154 (2005).
85. M. Chinol, P. Casalini, M. Maggiolo, S. Canevari, E. S. Omodeo, P. Caliceti, F. M. Veronese, M. Cremonesi, F. Chiolerio, E. Nardone, A. G. Siccardi, and G. Paganelli, British J. Cancer 79, 189 (1998).
86. T. Uchio, M. Baudys, F. Liu, S. C. Song, and S. W. Kim, Adv. Drug Deliv. Rev. 35, 289 (1999).
87. Z. Siprashvili, J. A. Reuter, and P. A. Khavari, Mol. Ther. 9, 721 (2004).
88. (a) R. J. Christie and D. W. Grainger, Adv. Drug Deliv. Rev. 55, 421 (2003);
89. (b) C. Bies, C. M. Lehr, and J. F. Woodley, Adv. Drug Deliv. Rev. 56, 425 (2004).
90. S. R. Myers, F. E. Yakubu-Madus, W. T. Johnson, J. E. Baker, T. S. Cusick, V. K. Williams, F. C. Tinsley, A. Kriauciunas, J. Manetta, and V. J. Chen, Diabetes. 46, 637 (1997).
91. J. Chopineau, S. Robert, L. Fénart, R. Cecchelli, B. Lagoutte, S. Paitier, M. P. Dehouck, and D. Domurado, J. Control. Rel. 56, 231 (1998).
92. R. Duncan and F. Spreafico, Clin. Pharmacokinet. 27, 290 (1994).
93. F. M. Veronese and P. Caliceti, Custom-Tailored PK and PD via Chemical Modifications of Biotech Drugs, in Pharmacokinetics and Pharmacodynamics of Biotech Drugs, Wiley-VCH, New York, In press.
94. F. M. Veronese and P. Caliceti, Bioconjugation and Biodistribution, in Cancer Drug Discovery and Development Tumour Targeting in Cancer Therapy, edited by M. Page, Humana Press Inc. New York (2005), pp. 411-429.
95. P. Caliceti and F. M. Veronese, Adv. Drug Deliv. Rev. 55, 1261 (2003).
96. T. Yamaoka, Y. Tabata, and Y. Ikada, J. Pharm. Sci. 84, 349 (1995).
97. G. Gregoriadis, B. McCormack, Z. Wang, and R. Lifely, FEBS Lett. 315, 271 (1993).
98. H. D. Hirst, S. Jain, D. Genkin, P. Laing, and G. Gregoriadis, Preparation and Properties of Polysialylated Interferon α-2b, AAPS Annual Meeting. Toronto (2002), p. M1056.
99. S. Jain, A. Bacon, D. H. Hreczuk-Hirst, B. McCormack, W. Caparros-Wanderley, A. A. Epenetos, P. Laing, and G. Gregoriadis, The Effect of Polysialylation on the Immunogenicity and Antigenicity of Insulin: Implications for its in vitro and in vivo Activity. Controled Release Society 30th Annual Meeting Proceedings, Glasgow, 441, 20 (2003).
100. A. Fernandes and G. Gregoriadis, Biochim. Biophys. Acta. 1341, 26 (1997).
101. A. Fernandes and G. Gregoriadis, Int. J. Pharm. 217, 215 (2001).
102. S. Jain, D. H. Hreczuk-Hirst, B. McCormack, M. Mital, A. Epenetos, P. Laing, and G. Gregoriadis, Biochim. Biophys. Acta. 1622, 42 (2003).
103. H. Bader, H. Ringsdorf, and B. Schmidt, Angew. Makromol. Chem. 123/124, 457 (1984).
104. D. Oupický, K. Ulbrich, and B. Říhová, J. Bioact. Compat. Polym. 14, 213 (1999).
105. B. Jeong, S. W. Kim, and Y. H. Bae, Adv. Drug Deliv. Rev. 54, 37 (2002).
106. Z. Ding, G. Chen, and A. S. Hoffman, Bioconjug Chem. 7, 121 (1996).
107. S. Salmaso, S. Pennadam, D. Cunliffe, C. Alexander, D. Górecki, and P. Caliceti, Physico-Chemical and Pharmacokinetic Studies of Avidin Bioconjugates with Thermosensitive Polymers. Controlled Release Society 32nd Annual Meeting, Miami 18-22, 412 (2005).
108. M. Mustafaev, Y. Osada, M. Matsukata, A. Basalp, B. Çirakoǧ lu, and E. Bermek, Pol. Gels Net. 4, 363 (1996).
109. A. S. Dilgimen, Z. Mustafaeva, M. Demchenko, T. Kaneko, Y. Osada, and M. Mustafaev Biomaterials, 22, 2383 (2001).
110. P. Bailon and W. Berthold, Pharm.l Sci. Technol. Today. 1, 352 (1998).
111. J. Milton Harris (Ed.), Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications, Plenum Press, New York (1991).
112. M. J. Roberts, M. D. Bentley, and J. M. Harris, Adv. Drug Deliv. Rev. 54, 459 (2002).
113. M. L. Graham, Adv. Drug Deliv. Rev. 55, 1293 (2003).
114. M. J. Knauff, D. P. Bell, P. Hirtzer, Z. P. Luo, J. D. Young, and N. V. Kartre, J. Biol. Chem. 263, 15064 (1988).
115. P. Caliceti, M. Chinol, M. Roldo, F. M. Veronese, A. Semenzato, S. Salmaso, and G. Paganelli, J. Control. Rel. 83, 97 (2002).
116. P. Caliceti, M. Chinol, G. Paganelli, S. Salmaso, and A. Semenzato, Biochim. Biophys. Acta. 1726, 57 (2005).
117. F. M. Veronese, P. Caliceti, and O. Schiavon, J. Bioact. Comp. Pol. 12, 196 (1997).
118. F. M. Veronese, C. Monfardini, P. Caliceti, O. Schiavon, M. D. Scrawen, and D. Beer, J. Control. Rel. 40, 199 (1996).
119. P. Caliceti, O. Schiavon, and F. M. Veronese, Bioconjug. Chem. 12, 515 (2001).
120. A. W. Richter and E. Akerblom, Int. Arch. Allergy Appl. Immunol. 70, 124 (1983).
121. C. Delgado, G. E. Francis, and D. Fisher, Crit. Rev. Then Drug Carrier Syst. 9, 249 (1992).
122. A. H. Sehon, Adv. Drug Deliv. Rev. 6, 203 (1991).
123. P. Caliceti, F. M. Veronese, and Z. Jonak, Il Farmaco. 54, 430 (1999).
124. S. Bowen, N. Tare, T. Inoue, M. Yamasaki, M. Okabe, I. Horii, and J. F. Eliason, Exp. Hematol. 27, 425 (1999).
125. L. B. Seeff and J. H. Hoofnagle, Clin. Liver Dis. 7, 261 (2003).
126. P. Bailon, C. L. Spence, C. A. Schaffer, K. Prinzo, S. Monkrash, J. E. Porter, W. J. Fung, W. E. DePinto, A. Aglione, L. Stern, G. Truitt, A. Pulleroni, Z. X. Xu, J. Hoffman, S. Pedder, and M. Brunda, Antivir. Ther. 4, 27 (1999).
127. K. R. Reddy, M. W. Modi, and S. Pedder, Adv. Drug Deliv. Rev. 54, 571 (2002).
128. Y. S. Wang, S. Youngster, M. Grace, J. Bausch, R. Bordens, and D. F. Wyss, Adv. Drug Deliv. Rev. 54, 547 (2002).
129. P. Caliceti, M. Morpurgo, O. Schiavon, C. Monfardini, and F. M. Veronese, J. Bioact. Comp. Pol. 9, 252 (1994).
130. P. Caliceti, O. Schiavon, L. Sartore, C. Monfardini, and F. M. Veronese, J. Bioact. Comp. Pol. 8, 41 (1993).
131. P. Esposito, L. Barbero, P. Caccia, P. Caliceti, M. D'Antonio, G. Piquet, and F. M. Veronese, Adv. Drug Deliv. Rev. 55, 1279 (2003).
132. O. Kinstler, G. Molineux, M. Treuheit, D. Ladd, and C. Gegg, Adv. Drug Deliv. Rev. 54, 477 (2002).
133. O. B. Kinstler, D. N. Brems, S. L. Lauren, A. G. Paige, J. B. Hamburger, and M. J. Treuheit, Pharm. Res. 13, 996 (1996).
134. Q. Yun, T. Chen, G. Zhang, J. Bi, G. Ma, and Z. Su, Biotechnol. Lett. 27, 213 (2005).
135. H. F. Gaertner and R. E. Offord, Bioconjug. Chem. 7, 38 (1996).
136. M. S. Rosendhal, D. H. Dohetty, D. J. Smith, A. M. Bende, and G. N. Cox, Bioprocess International (2005), pp. 52-62.
137. W. J. Fung, J. E. Porter, and P. Bailon, Polym. Prepr. 38, 565 (1997).
138. A. Deiters, T. A. Cropp, D. Summerer, M. Mukherji, and P. G. Schultz, Bioorg. Med. Chem. Letters. 14, 5743 (2004).
139. S. Zalipsky, Adv. Drug Deliv. Rev. 16, 157 (1995).
140. K. D. Hinds and S. W. Kim, Adv. Drug Deliv. Rev. 54, 505 (2002).
141. P. Caliceti, F. M. Veronese, Successful Insulin Delivery by PEG Conjugation. 25th International Symposium, on Controlled Release of Bioactive Materials, Las Vegas, 347 (1998).
142. H. Sato, Adv. Drug Deliv. Rev. 54, 487 (2002).
143. S. Chiruvolu, S. Walker, J. Israelachvili, F. J. Schmitt, D. Leckband, and J. A. Zasadzinski, Science 264, 1753 (1994).
144. L. Yang and P. Alexandridis, Curr. Opin. Coll. Interf. Sci. 5, 132 (2000).
145. P. H. Demana, N. M. Davies, B. Berger, and T. Rades, Intern. J. Pharm. 278, 263 (2004).
146. Y. Liu, X. Y. Dong, and Y. Sun, J. Colloid Interf. Sci. 290, 259 (2005).
147. C. La Mesa, J. Colloid Interf. Sci. 286, 148 (2005).
148. V. Peyre, V. Lair, V. Andre, G. le Maire, and U. Kragh-Hansen, M. le Maire, and J. V. Moller, Langmuir. 21, 8865 (2005).
149. A. Harada and K. Kataoka, Macromolecules 31, 288 (1998).
150. H. Yoshikawa, K. Takada, S. Muranishi, Y. Satoh, and N. Naruse, J. Pharmacobiodyn. 7, 59 (1984).
151. V. Weissig, K. R. Whiteman, and V. P. Torchilin, Pharm. Res. 15, 1552 (1998).
152. T. Ooya, and N. Yui, J. Control. Rel. 80, 219 (2002).
153. A. Nelson, J. M. Belitsky, S. Vidai, C. S. Joiner, L. G. Baum, and J. F. Stoddart, J. Am. Chem. Soc. 126, 11914 (2004).
154. A. Constancis, R. Meyrueix, N. Bryson, S. Huille, J. M. Grosselin, T. Gulik-Krzywicki, and G. Soula, J. Colloid. Interf. Sci. 217, 357 (1999).
155. O. Soula, R. Meyrueix, Y. P. Chan, C. Grangeon, R. Kravtzoff, and G. Soula, Sustained Release of IL-2 from Medusa® Comb-Like Hydrophobically Modified Polyglutammate. CAS 30th Annual Meeting, Glasgow (2003), p. 690.
156. R. Meyrueix, J. P. Lecompte, O. Soula, G. Pouliquen, P. Y. Chan, F. Nicolas, R. Kravtzoff, and G. Soula, Sustained, release of Interferon alpha 2b from Medusa® Nanoparticles of Comb-Like Hydrophobically Modified Polyglutammate, CRS 30th Annual Meeting, Glasgow (2005), p. 688.
157. Y. Nomura, M. Ikeda, N. Yamaguchi, Y. Aoyama, and K. Akiyoshi, FEBS Lett. 553, 271 (2003).
158. K. Akiyoshi, S. Kobayashi, S. Shichibe, D. Mix, M. Baudys, S. W. Kim, and J. Sunamoto J. Control. Rel. 54, 313 (1998).
159. A. P. Villalobos, S. R. Gunturi, and G. A. Heavner, Pharm Res. 22, 1186 (2005).
160. Y. Pellequer, M. Ollivon, and G. Barratt, Biomed Pharmacother. 58, 162 (2004).
161. D. Zelihagü, I, Ü. I, Nilay, E. Dinç, and A. Ufuk, The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer Life Sciences. 75, 2819-2827 (2004).
162. H. Takeuchi, H. Yamamoto, and Y. Kawashima, Adv. Drug Deliv. Rev. 47, 39 (2001).
163. H. Takeuchi, H. Yamamoto, T. Niwa, T. Hino, and Y. Kawashima, Pharm. Res. 13, 896 (1996).
164. H. Takeuchi, Y. Matsui, H. Yamamoto, and Y. Kawashima, J. Control. Rel. 86, 235 (2003).
165. L. Leserman, J. Liposome Res. 14, 175 (2004).
166. M. L. Van Slooten, O., Boerman, K. Romøren, E. Kedar, D. J. A. Crommelin, and G. Storm, Biochim. Biophys. Acta. 1530, 134 (2001).